CTIS2022-502126-40-00进行中（未招募）1 期
A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study - MK-8591A-054
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,312
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Is currently receiving doravirine/islatravir (DOR/ISL) adult fixed dose combination (FDC) tablet in Merck Sharp & Dohme (MSD)-sponsored clinical studies (MK-8591A-017, -018, -020, and -033 [except for heavily treatment-experienced (HTE) participants]).
排除标准
- •Has confirmed HIV-1 RNA =200 copies/mL in MSD DOR/ISL (100 mg/0.75 mg) MK-8591A-017 /-018 /-020, or at screening for participants entering from DOR/ISL (100 mg/0.75 mg) MK-8591A-033., Has confirmatory laboratory findings for cluster of differentiation 4+ (CD4+) T-cell counts or lymphocyte counts in the prior DOR/ISL study that meet criteria for discontinuation of DOR/ISL., Is a HTE participant receiving treatment in MK-8591A-019 or -033.
研究者
相似试验
进行中（未招募）
3 期
Follow-up of Participants Who Received DOR/ISL (100 mg/0.75 mg)HIV-1 InfectionJPRN-jRCT2051230002Tanaka Yoshiyuki1,300
进行中（未招募）
3 期
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)HIV InfectionNCT05766501Merck Sharp & Dohme LLC641
已完成
3 期
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia SyndromeSevere Fever with Thrombocytopenia Syndrome (SFTS)JPRN-jRCT2080223816FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)30
招募中
3 期
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionNCT06203132ANRS, Emerging Infectious Diseases610
已完成
3 期
DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIVHIV-1-infectionNCT04433780Professor Francois Venter133